logo-loader
Silence Therapeutics PLC

Silence Therapeutics finance chief departs

Silence’s group head of financial planning and analysis, Rob Quinn, will take on the outgoing David Ellam’s responsibilities for the time being whilst a permanent successor is found

director leaving office
CEO David Horn Solomon wished Ellam all the best for the future

The chief financial officer of Silence Therapeutics PLC (LON:SLN), David Ellam, has left the gene editing specialist with immediate effect.

Silence’s group head of financial planning and analysis, Rob Quinn, will take on Ellam’s responsibilities for the time being whilst a permanent successor is found.

READ: Silence adds new siRNA asset to pre-clinical pipeline

“On behalf of the board I would like to thank David for his contribution to Silence,” said chief executive David Horn Solomon.

“He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.”

Quick facts: Silence Therapeutics PLC

Price: £2.00

Market: AIM
Market Cap: £155.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics hails 'transformational' deal with US firm Mallinckrodt

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses the partnership they've struck with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) to develop and commercialise gene silencing treatments for serious diseases. Mallinckrodt will obtain an exclusive worldwide license to...

3 weeks, 6 days ago

RNS

Notice of Results and R&D day

2 days, 21 hours ago

Additional Listing

4 days, 21 hours ago

Additional Listing

1 week, 3 days ago

Additional Listing

1 week, 4 days ago

Additional Listing

1 week, 5 days ago

Holding(s) in Company

2 weeks, 3 days ago

Holding(s) in Company

2 weeks, 4 days ago

2 min read